<?xml version="1.0" encoding="UTF-8"?>
<snippetsTree>
 <snippets file="drug\PMC7536086\results\search\testTrace\results.xml">
  <result pre="Review Article Convalescent plasma therapy: a promising coronavirus disease 2019" exact="treatment" post="strategy Plasma therapy a possible hope to fight PiyushRavikant1â€"/>
  <result pre="the outbreak of disease has spawned a corpus of contagious" exact="infection" post="all over the world, day by day, without control."/>
  <result pre="acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has a very rapid" exact="infection" post="rate, it is essential to develop a novel ameliorative"/>
  <result pre="two decades. For example, CP therapy was used in the" exact="treatment" post="of viral-induced diseases like SARS-CoV epidemics, Middle East respiratory"/>
  <result pre="present at the genome's 5â€²-end [5,13]. Until now, no specific" exact="treatment" post="has been discovered to be completely effective against the"/>
  <result pre="is still struggling to develop a potent vaccine to prevent" exact="infection" post="[14]. Presently, the management of SARS-CoV-2-infected patients basically emphasizes"/>
  <result pre="by several countries to treat patients suffering from severe SARS-CoV-2" exact="infection" post="[18,19]. CP has proved its effectiveness in neutralizing viruses"/>
  <result pre="CP therapy has been explored for an effective line of" exact="treatment" post="[20,21]. 1.1. SARS-CoV-2 pathogenesis and immune response SARS-CoV-2 was"/>
  <result pre="not all infected persons acquire severe respiratory illness. This differential" exact="infection" post="and illness may depend upon the immune response of"/>
  <result pre="response of individuals. Based on the differential response, the SARS-CoV-2" exact="infection" post="is clinically categorized into mainly two stages [16]: non-severe"/>
  <result pre="stages [16]: non-severe and severe. 1.1.1. Non-severe stage To prevent" exact="infection" post="at an initial stage, a specific adaptive immune response"/>
  <result pre="background, the immune system of individuals responds differently to the" exact="infection" post="[29]. 1.1.2. Severe stage This is also known as"/>
  <result pre="of passive antibody therapy In order to treat or prevent" exact="infection" post="of particular diseases, the susceptible individual is administered with"/>
  <result pre="active immune response develops against any diseases either due to" exact="infection" post="from a pathogen or due to the administration of"/>
  <result pre="for prevention or prophylaxis rather than for the cure or" exact="treatment" post="of the disease. When the antibodies are used for"/>
  <result pre="indispositions [55]. Despite this fact, they may not yield appropriate" exact="infection" post="control and are quite difficult and expensive to produce."/>
  <result pre="as the first therapeutic alternative and sometimes as an experimental" exact="treatment" post="or last resort [45]. 3. The strategy of convalescent"/>
  <result pre="safety of the recipients, it is compulsory to perform a" exact="nucleic acid test" post="for HIV and hepatitis viruses [69]. Neutralization of pathogens"/>
  <result pre="antibodies play a crucial role in the elimination of viral" exact="infection" post="and are believed to be essential in prevention from"/>
  <result pre="domains of S protein, and thereby help in controlling the" exact="infection" post="[74]. Furthermore, CP administration is also known to enhance"/>
  <result pre="are at their maximum during the first week of the" exact="infection" post="[56]. After the onset of symptoms in the second"/>
  <result pre="using CP therapy Due to the absence of any specified" exact="treatment" post="for COVID-19, researchers are still searching for potential therapeutic"/>
  <result pre="searching for potential therapeutic agents and an effective line of" exact="treatment" post="to contain the disease. The implementation of CP therapy"/>
  <result pre="was checked based on its past trials and the successful" exact="treatment" post="of several viral-mediated epidemics and pandemics [84]. To date,"/>
  <result pre="the efficacy of CP therapy in curing patients with SARS-CoV-2" exact="infection" post="[54,85,86]. TableÂ 1 precisely enlists the CP administration in"/>
  <result pre="clinical outcomes by neutralizing viraemia in patients with critical SARS-CoV-2" exact="infection" post="and can serve as a promising rescue option for"/>
  <result pre="comprising the neutralizing antibodies, at an early stage of COVID-19" exact="infection" post="can prevent the inflammatory response induced by SARS-CoV-2. The"/>
  <result pre="CP therapy has been a prevalent and effective mode of" exact="treatment" post="in various viral infections in the past (e.g. Ebola,"/>
  <result pre="explored further to make it suitable and effective in the" exact="treatment" post="of the patients infected with SARS-CoV-2. In summary, the"/>
  <result pre="(10.1016/j.dsx.2020.04.015)32334392 18IslamA, RafiqS, KarimS, LaherI, RashidH2020Convalescent plasma therapy in the" exact="treatment" post="of COVID-19: practical considerations: correspondence. Int. J. Surg.79, 204â€&quot;205."/>
  <result pre="J. Clin. Invest.130, 1545â€&quot;1548. (10.1172/JCI138003)32167489 33SawyerL2000Antibodies for the prevention and" exact="treatment" post="of viral diseases. Antiviral Res.47, 57â€&quot;77. (10.1016/s0166-3542(00)00111-x)10996394 34ClemAS2011Fundamentals of"/>
  <result pre="al.2014The effectiveness of convalescent plasma and hyperimmune immunoglobulin for the" exact="treatment" post="of severe acute respiratory infections of viral etiology: a"/>
  <result pre="experience on the use of extracorporeal membrane oxygenation for the" exact="treatment" post="of influenza A (H1N1). Hong Kong Med. J.16, 447â€&quot;454.21135421"/>
  <result pre="infection. N. Engl. J. Med.357, 1450â€&quot;1451. (10.1056/NEJMc070359)17914053 58HungIFet al.2011Convalescent plasma" exact="treatment" post="reduced mortality in patients with severe pandemic Influenza A"/>
  <result pre="al.2015The effectiveness of convalescent plasma and hyperimmune immunoglobulin for the" exact="treatment" post="of severe acute respiratory infections of viral etiology: a"/>
  <result pre="(10.1016/j.lpm.2016.06.016) 67BlochEMet al.2020Deployment of convalescent plasma for the prevention and" exact="treatment" post="of COVID-19. J. Clin. Investig.130, 2757â€&quot;2765. (10.1172/JCI138745)32254064 68DoddRY, CrowderLA,"/>
  <result pre="BhattiFA, SalamatN, GhaniE, TayyabM2015Impact of nucleic acid amplification test on" exact="screening" post="of blood donors in Northern Pakistan. Transfusion55, 1803â€&quot;1811. (10.1111/trf.13017)25648663"/>
  <result pre="NarayanasamyK, RangarajanJ, RathinamJ, NatarajanM, RamachandranA.In press.Convalescent plasma transfusion for the" exact="treatment" post="of COVID-19: systematic review.J. Med. Virol. (10.1002/jmv.25961) 74DuL, HeY,"/>
  <result pre="YangP-C2004Chronological evolution of IgM, IgA, IgG and neutralisation antibodies after" exact="infection" post="with SARS-associated coronavirus. Clin. Microbiol. Infect.10, 1062â€&quot;1066. (10.1111/j.1469-0691.2004.01009.x)15606632 76GorseGJ,"/>
  <result pre="recovered from Ebola virus disease for transfusion, as an empirical" exact="treatment" post="during outbreaks: interim guidance for national health authorities and"/>
  <result pre="Ann. Lab. Med.36, 393â€&quot;395. (10.3343/alm.2016.36.4.393)27139619 93GuptaSS, GuptaAK, ChandakP, KumariJ2020Convalescent sera:" exact="treatment" post="for novel and enigmatic Covid-19. EPRA International Journal of"/>
 </snippets>
</snippetsTree>
